Adcetris (brentuximab vedotin) redefined Hodgkin lymphoma treatment with its approval in 2011, becoming the backbone of Hodgkin lymphoma therapy. It is currently approved in all lines of treatment. The arrival of PD-1 inhibitors such as Keytruda (pembrolizumab) and Opdivo (nivolumab) boosted treatment options for this indication.
Up to now, PD-1 inhibitors have been viewed as options following Adcetris treatment. However, results from the Phase III KEYNOTE-204 trial comparing Keytruda versus Adcetris suggest potential for Keytruda to move up in the treatment paradigm, with the potential to replace Adcetris. Read more here.